At BCCDC, Dr. Janjua provides leadership on surveillance, research and policy advice, and programming related to hepatitis B and C in British Columbia.
His research interests include hepatitis B and C epidemiology, syndemics of substance use, mental illness and blood-borne and sexually transmitted infections, intervention effectiveness, disparities in treatment access and disease outcomes, and strategies to enhance access to care.
Read Less Read MoreMost of his current work is based on the BC Hepatitis Testers Cohort. His global health research includes unsafe medical injections and transmission of bloodborne pathogens, socio-economic disparities in health, and scale-up of hepatitis testing and treatment in South Asia developing countries. He has been involved in initiatives to design and scale-up testing, linkage with care and treatment for HCV in various settings. He is also a member of various national networks including the Canadian Hepatitis C Network (CanHepC) and the CIHR Canadian HIV Trials Network (CTN).
The first Evidence Speaks of 2023 features mask mandate effectiveness, client preferences for iOAT delivery, and patient-reported outcomes following hysterectomy
Read More
Discover new research on use of opioids and stimulants and risk of overdose, risk of heart conditions following second doses of COVID vaccines, and occupational and financial setbacks in caregivers of people with cancer
Read More
September's edition includes severity of the Omicron versus Delta COVID-19 variants, pre- and in-hospital factors that impact outcomes of cardiac arrest, and long-acting contraceptive use among Ugandan women
Read More
